



W/D 1642 \$WD
Patent Docket P1085R3
(Box, Sg)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Vanessa Hsei et al. Serial No.: 09/355,014 Filed: July 21, 1999 For: ANTIBODY FRAGMENT- POLYMER CONJUGATES AND HUMANIZED ANTI-IL-8 MONOCLONAL ANTIBODIES		Group Art Unit: 1642	RECEIVED
		Examiner: L. Helms	FEB 01 2001
		TECH CENTER 1600/2900	
		CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on January 25, 2001  Richard B. Love	

RECEIVED
FEB 02 2001
TECH CENTER 1600/2900

TRANSMITTAL LETTER

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Transmitted herewith are the following documents:

1. Postcard
2. Transmittal
3. Petition to Extend Time (five month Ext. of Time)
4. Amendment Transmittal
5. Amendment
6. Sequence Listing with diskette
7. Substitute Specification
8. Marked-up copy of Original Specification
9. Certification Re: Sequence Listing
10. Statement Under 37 C.F.R. §1.125 and MPEP 608.01(q)

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

Date: January 25, 2001

GENENTECH, INC.

By: Richard B. Love

Richard B. Love

Reg. No. 34,659

Telephone No. (650) 225-5530



09157 PATENT TRADEMARK OFFICE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

In re Application of Vanessa Hsei et al. Serial No.: 09/355,014 Filed: July 21, 1999 For: ANTIBODY FRAGMENT- POLYMER CONJUGATES AND HUMANIZED ANTI-IL-8 MONOCLONAL ANTIBODIES	Group Art Unit: 1642 Examiner: L. Helms CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on January 25, 2001 <i>Richard B. Love</i> Richard B. Love	FEB 01 2001 TECH CENTER 1600/2900 RECEIVED FEB 02 2001
--	---	---

AMENDMENT TRANSMITTAL

TECH CENTER 1600/2900

Assistant Commissioner of Patents
 Washington, D.C. 20231

Sir:

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated as shown below.

	Claims Remaining After Amendment		Highest No. Previously Paid For	Present Extra	Rate	Additional Fees
Total	52	-	54	0	18	\$0.00
Independent	4	-	4	0	78	\$0.00
__ Multiple dependent claim(s), if any					260	\$0.00
Total Fee Calculation						\$0.00

 X

 X

No additional fee is required.

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630
 in the amount of \$. **A duplicate copy of this transmittal is enclosed.**
 Petition for Extension of Time is enclosed.

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17,
 or credit overpayment to Deposit Account No. 07-0630. **A duplicate copy of this sheet is enclosed.**

Respectfully submitted,
 GENENTECH, INC.



Date: January 25, 2001

By: *Richard B. Love*
 Richard B. Love
 Reg. No. 34,659
 Telephone No. (650) 225-5530



09157

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Vanessa Hsei et al. Serial No.: 09/355,014 Filed: July 21, 1999 For: ANTIBODY FRAGMENT- POLYMER CONJUGATES AND HUMANIZED ANTI-IL-8 MONOCLONAL ANTIBODIES	 Group Art Unit: 1642 Examiner: L. Helms CERTIFICATE OF MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on January 25, 2001  Richard B. Love
--	---

STATEMENT UNDER 37 C.F.R. §1.125 AND MPEP 608.01(q)


Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

Attached to the present Statement is a substitute specification the entry of which is respectfully requested. Also attached hereto is a marked-up copy of the original specification which shows the portions of the original specification that are modified in the substitute specification (excluding the Sequence Listing). The substitute specification introduces no new matter, and contains the same changes as those indicated in the marked-up copy of the original specification along with a Sequence Listing as required under C.F.R. §§1.821-1.825.

Respectfully submitted,
GENENTECH, INC.

Date: January 25, 2001

By: 
Richard B. Love
Reg. No. 34,659
Attorney for Applicants

1 DNA Way
So. San Francisco, CA 94080-4990
Phone: (650) 225-5530
Fax: (650) 952-9881